Expressing support for the designation of June 19, 2025, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease.
- Bill Number
- H.Res. 524
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-20: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-07-08T15:17:33Z
AI-Generated Summary
Purpose
This House Resolution (H. Res. 524) expresses support for designating June 19, 2025, as "World Sickle Cell Awareness Day." Its main goal is to raise public awareness in the United States and globally about sickle cell disease (SCD)—a group of inherited blood disorders—and the ongoing needs for research, early screenings, new treatments (including potential cures), and preventive care to manage complications like pain crises, anemia, strokes, and organ damage.
Key Provisions
The resolution includes a detailed preamble highlighting facts about SCD and sickle cell trait (SCT, a carrier state where a person has one copy of the mutated gene but usually no symptoms). It then resolves that the House of Representatives:
- Supports the goals and ideals of World Sickle Cell Awareness Day, with the 2025 theme "Global Action, Local Impact: Empowering Communities for Effective Self-Advocacy."
- Commits to promoting equitable access to SCD treatments across all economic, racial, and ethnic groups to improve health outcomes.
- Calls on the Department of Health and Human Services (HHS) to develop global policy solutions, partnering with local governments to provide newborn screenings, therapies, and support services for SCD.
- Supports removing barriers to innovative treatments (like cell, gene, and gene-editing therapies) in Medicare and Medicaid programs, especially for vulnerable patients.
- Encourages people in the U.S. and worldwide to organize events, programs, and activities on June 19, 2025, to educate about SCD traits, preventive care, treatments, and patient services.
- Urges the President to establish a Sickle Cell Disease Interagency Group, involving HHS, the Department of Veterans Affairs, National Institutes of Health (NIH), Food and Drug Administration (FDA), and Centers for Medicare & Medicaid Services (CMS), to advance policies for equitable access to new therapies.
- Directs the interagency group to address not only access to future cures but also biases faced by SCD-affected populations in U.S. and global healthcare systems.
The preamble also notes historical context, such as the 1972 National Sickle Cell Anemia Control Act (the first federal law funding SCD programs), global prevalence (especially in Africa and among African-American and Hispanic-American communities), limited treatments (only four FDA-approved since 2017, plus two gene therapies in 2023), and the role of hematopoietic stem cell transplantation (HSCT, a bone marrow transplant) as the only current cure.
Significant Changes to Existing Law
This is a non-binding resolution, so it introduces no legal changes or new enforceable requirements. It builds on prior laws like the 1972 Act and references recent reports (e.g., from the National Academies in 2020) but does not amend statutes or create mandates.
Potential Impacts
- On government agencies: Encourages coordination among HHS, NIH, FDA, CMS, and others through a proposed interagency group, potentially leading to new policies on SCD screening, treatment access, and global partnerships. This could influence funding priorities and reduce healthcare disparities without requiring new budgets.
- On citizens: Increases awareness of SCD (affecting about 100,000 Americans, mostly African-American and Hispanic-American individuals) and SCT (carried by 1-3 million unaware Americans), promoting early detection and preventive care to lower mortality (e.g., 50% of African children with SCD die before age 5). It aims to improve quality of life through better access to therapies, especially for low-income and minority groups.
- On international relations: Supports global efforts, aligning with UN and World Health Organization resolutions on SCD as a public health priority. It could foster U.S. collaborations with countries in Africa, South America, and elsewhere to share resources for screenings and treatments, potentially aiding resource-poor regions where SCD is highly prevalent.
Main Stakeholders Affected
- Individuals and families with SCD or SCT: Primarily African-American (1 in 365 births affected), Hispanic-American (1 in 16,300 births), and global populations from sub-Saharan Africa, South/Central America, India, Saudi Arabia, and the Mediterranean.
- Healthcare providers and organizations: Groups like the Sickle Cell Disease Association of America, American Society of Hematology, and SickleInAfrica Consortium, which could benefit from increased advocacy and research support.
- Government entities: HHS, NIH, FDA, CMS, and the Department of Veterans Affairs, tasked with policy development and equitable access.
- Communities and advocates: Underserved racial/ethnic groups facing healthcare biases; researchers and patients pushing for cures like gene therapies or HSCT.
Notable Legal, Constitutional, or Political Implications
- Legal: As a simple resolution, it has no force of law and requires no presidential signature, but it signals congressional intent and could inspire future binding legislation (e.g., expanding the 1972 Act).
- Constitutional: Aligns with Congress's role in promoting general welfare (Article I, Section 8) by addressing public health without infringing on states' rights or individual liberties.
- Political: Demonstrates bipartisan support for health equity and minority-focused issues (introduced by Rep. Davis and Rep. Sewell), potentially influencing elections or funding debates. It highlights systemic biases in healthcare, promoting anti-discrimination efforts without mandating changes, and underscores U.S. leadership in global health amid challenges like the COVID-19 pandemic.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Rep. Sewell, Terri A. [D-AL-7], Rep. Vindman, Eugene Simon [D-VA-7]
Recent Actions
- 2025-06-20: Referred to the House Committee on Energy and Commerce.
- 2025-06-20: Submitted in House
- 2025-06-20: Submitted in House
Bill Versions
- Expressing support for the designation of June 19, 2025, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease. — issued 2025-06-20 — PDF (7 pages)